Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.185 EUR | -0.23% | +0.69% | -16.60% |
Mar. 21 | Transcript : Innate Pharma S.A., 2023 Earnings Call, Mar 21, 2024 | |
Mar. 06 | Innate Pharma initiates lymphoma trial | CF |
Sales 2023 | 61.64M 66.48M | Sales 2024 * | 47.99M 51.75M | Capitalization | 177M 191M |
---|---|---|---|---|---|
Net income 2023 | -7M -7.55M | Net income 2024 * | -29M -31.28M | EV / Sales 2023 | 3.43 x |
Net cash position 2023 * | 29.41M 31.72M | Net cash position 2024 * | 25.2M 27.18M | EV / Sales 2024 * | 3.16 x |
P/E ratio 2023 |
-29.1
x | P/E ratio 2024 * |
10.4
x | Employees | 191 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 75.5% |
Latest transcript on Innate Pharma
1 day | -0.23% | ||
1 week | +0.69% | ||
1 month | -7.42% | ||
3 months | -14.65% | ||
6 months | -13.98% | ||
Current year | -16.60% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Vivier
FOU | Founder | 59 | 99-09-22 |
Chief Executive Officer | 62 | 99-09-22 | |
Frederic Lombard
DFI | Director of Finance/CFO | 49 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 99-09-22 | |
Gilles Brisson
BRD | Director/Board Member | 72 | 07-06-25 |
Olivier Martinez
BRD | Director/Board Member | 54 | 10-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.185 | -0.23% | 40,353 |
24-03-27 | 2.19 | -0.23% | 53,254 |
24-03-26 | 2.195 | +0.69% | 26,812 |
24-03-25 | 2.18 | +0.69% | 32,842 |
24-03-22 | 2.165 | -0.23% | 25,864 |
Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.60% | 191M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |